As organizations race to adopt artificial intelligence, the conversation has increasingly shifted from raw model performance to a more practical question: how can enterprises run AI at lower cost ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

LinkDaddy has expanded Cloud Authority Backlinks, a multi-cloud SEO system that delivers DoFollow backlinks, machine-readable authority signals, and AI-ready content architecture for businesses and ...

The most capable one didn't make the cut.

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...

Brand-new startups are continuing to raise massive rounds to work on new niches of AI. Recursive, a stealth-mode AI lab, has emerged from the shadows with one an audacious pitch: build an AI that ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.